Non-Invasive Current Stimulation Improves Sight and Quality of Life in Patients with Optic Nerve Damage
Potential new therapy for patients with loss of vision
Potential new therapy for patients with loss of vision
Magdeburg, Germany, October 31, 2011 - It has long been thought that blindness after brain lesions is irreversible and that damage to the optic nerves leads to permanent impairments in everyday activities such as reading, driving, and spatial orientation. A new study published in Elsevier’s Brain Stimulation suggests that treating such patients with low levels of non-invasive, repetitive, transorbital alternating current stimulation (rtACS) for 10 days (30-40 min per day) significantly reduces visual impairment and markedly improves vision-related quality of life.
The results of this study showed that treatment with rtACS resulted in an average of 41% shrinkage of the visual field loss. The rtACS-treated patients show significantly improved visual field sizes, which was not seen in patients who received sham treatment. Actively treated patients confirmed that their “general vision” was improved. In the sham-group, visual fields and estimates of subjective visual functioning remained largely unchanged.
“Our findings are important because they show that partial blindness can be reversed. We show for the first time that partial blindness can be reduced by a short-lasting therapeutic procedure using non-invasive electrical current stimulation,” states Dr. Bernhard A. Sabel, researcher and senior author of this study
A group of 42 patients with visual impairments following optic nerve damage participated in the study. Patients were randomly assigned to either a control condition with sham stimulation or rtACS given with an alternating current stimulation device (EBS Technologies GmbH, Kleinmachnow, Germany) with electrodes positioned near the eyes. The length of the daily treatment session (both rtACS and sham-treatment) varied between 10 to 20 min for each eye, i.e. max 40 min. The optic nerve lesions were treated long after the early recovery phase (mean lesion age 5.5 yrs). Both patients and the experimenter evaluating the vision parameters were unaware to which treatment arm the patients belonged. The study’s idea was to enhance visual system plasticity by increasing synaptic strength of residual cells in the partially damaged visual system and thus improve any residual visual capacity. The study documents a considerable activation potential of residual vision following optic nerve damage. Current pulses administered to the eye in a non-invasive manner might be able to unveil this plasticity.
The researchers were particularly interested to learn if rtACS has an effect on self-estimated visual and health-related functioning as assessed by quality of life questionnaires (e.g., the National Eye Institute Visual Function Questionnaire, NEI-VFQ). Vision parameters and patient reported outcomes were collected before and after the 10-day treatment course.
The findings of this study are not only of interest to basic scientists, showing that the adult visual system is more modifiable than was previously thought, but may also help develop new therapies for patients with visual field loss. Improving vision in a subjectively meaningful way is a clinical achievement that reduces the suffering of the partially blind.
Additional studies are now underway to document in patients with visual dysfunction the neurobiological basis of the rtACS effects. Furthermore, a clinical trial with larger patient groups is currently underway to replicate these findings. Finally, the use of rtACS for the treatment of hemianopia after stroke is now being explored as well.
# # #
Notes for editors
This article is “Noninvasive transorbital alternating current stimulation improves subjective visual functioning and vision-related quality of life in optic neuropathy" (doi:10.1016/j.brs.2011.07.003 ) by C. Gall,S. Sgorzaly, S. Schmidt, S. Brandt, A. B. Fedorov, B. A. Sabel. The authors are affiliated with
the University of Magdeburg, Charité Campus Mitte, Berlin, and EBS Technologies GmbH, Kleinmachnow, Germany. The article appears in Brain Stimulation, Volume 4, Issue 4, October 2011, Pages 175-188, published by Elsevier.
About Brain Stimulation
Brain Stimulation is a premier journal for publication of original research in the field of neuromodulation. The journal includes: original articles, brief reports, invited and original reviews, technology and methodological perspectives (reviews of new devices, description of new methods, etc.); and letters to the editor.
The scope of Brain Stimulation extends across the entire field of brain stimulation, including noninvasive and invasive techniques and technologies that alter brain function through the use of electrical, magnetic, radiowave, or focally targeted pharmacologic stimulation. This includes investigations that study the effects of brain stimulation on basic processes, such as gene expression and other aspects of molecular biology, neurochemical regulation, functional brain activity, sensorimotor function, and cognitive and affective processes at the systems level.
The journal seeks the highest level of research on the biophysics and biopsychophysics of stimulation paradigms as well as the use of these techniques as a probe to outline patterns of neural connectivity. As an equal partner with this basic emphasis, the journal will have strong representation of research on the therapeutic potential and adverse effects of the stimulation technologies. The inclusion of research in therapeutics will represent not only clinical trials, but also conceptual pieces, discussions of ethics as they pertain to this field, services research, etc.
Elsevier is a global information analytics business that helps institutions and professionals advance healthcare, open science, and improve performance for the benefit of humanity. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, more than 35,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX Group, a global provider of information and analytics for professionals and business customers across industries. www.elsevier.com
+ 1 212 633 3962